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INTRODUCTION: Activating mutations in exon 3 of the b-catenin gene are involved in the pathogenesis of
adamantinomatous craniopharyngiomas. Recently, the interaction between b-catenin and PROP1 has been shown
to be responsible for pituitary cell lineage determination. We hypothesized that dysregulated PROP1 expression
could also be involved in the pathogenesis of craniopharyngiomas.
OBJECTIVES: To determine whether dysregulated gene expression was responsible for tumor pathogenesis in
adamantinomatous craniopharyngiomas, the b-catenin gene was screened for mutations, and the expression of the
b-catenin gene and PROP1 was evaluated.
METHODS: The b-catenin gene was amplified and sequenced from 14 samples of adamantinomatous
craniopharyngiomas. PROP1 and b-catenin gene expression was assessed by real-time RT-PCR from 12 samples,
and b-catenin immunohistochemistry was performed on 11 samples.
RESULTS: Mutations in the b-catenin gene were identified in 64% of the adamantinomatous craniopharyngiomas
samples. Evidence of b-catenin gene overexpression was found in 71% of the tumors with b-catenin mutations and
in 40% of the tumors without mutations, and b-catenin immunohistochemistry revealed a nuclear staining pattern
for each of the analyzed samples. PROP1 expression was undetectable in all of the tumor samples.
CONCLUSION: We found evidence of b-catenin gene overexpression in the majority of adamantinomatous
craniopharyngiomas, and we also detected a nuclear b-catenin staining pattern regardless of the presence of a b-
catenin gene mutation. These results suggest that WNT signaling activation plays an important role in the
pathogenesis of adamantinomatous craniopharyngiomas. Additionally, this study was the first to evaluate PROP1
expression in adamantinomatous craniopharyngiomas, and the absence of PROP1 expression indicates that this
gene is not involved in the pathogenesis of this tumor, at least in this cohort.
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INTRODUCTION
Craniopharyngiomas are rare intra/suprasellar neo-
plasms that account for 10% of all pediatric intracranial
tumors. During childhood, they are the most common
lesions involving the hypothalamo-pituitary regions.1
Craniopharyngiomas are histologically benign and can be
categorized into two primary subtypes with different
histopathological features: adamantinomatous and papil-
lary. The former is thought to arise from squamous cell rests
of the craniopharyngeal duct, which is a canal that connects
the stomodeal ectoderm with Rathke’s pouch,2,3 and the
latter subtype results from metaplasia of the adenohypo-
physeal cells in the pituitary gland.4 The adamantinomatous
craniopharyngioma is the most common histological type
and occurs at all ages, but it predominantly affects
individuals in the first two decades of life. Conversely,
papillary craniopharyngiomas have been almost exclusively
described in adults.5
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The pathogenesis of craniopharyngiomas is poorly under-
stood. To date, mutations in the b-catenin gene have been
identified only in the adamantinomatous subtype and at a
variable frequency.6-9 The b-catenin protein is encoded by
the CTNNB1 gene. The association of b-catenin with
cadherin adhesion molecules at the plasma membrane
provides a link between cadherins and the actin cytoskele-
ton, which is essential for strong cell-cell adhesion.10
Furthermore, b-catenin is a key mediator of the canonical
WNT signaling pathway, which is involved in the control
of stem cell pluripotency, cell proliferation, differentiation
and migration.11 b-catenin is regulated by a multiprotein
complex that contains the tumor suppressor protein
adenomatous polyposis coli (APC), the scaffold proteins
Axin and Axin2 and the phosphokinases glycogen synthase
kinase-3b (GSK-3b) and casein kinase 1. When WNT
signaling is inactive, b-catenin is phosphorylated within
the multiprotein complex; this phosphorylation results in its
ubiquitination and degradation by the proteasome.12
However, WNT activation inhibits GSK-3b, and b-catenin
is then able to avoid degradation and accumulate in the
cytoplasm. It is then translocated into the nucleus where it
binds to the transcription factor T cell factor (TCF)/
lymphoid enhancer factor (LEF) and thereby regulates gene
expression.13 The GSK-3b-binding domain of b-catenin
corresponds to its degradation targeting box and is encoded
by exon 3 of CTNNB1. Activating mutations within this
region, which have been described for the adamantinoma-
tous subtype but not the papillary subtype,6-9 promote b-
catenin accumulation through the inhibition of its degrada-
tion and lead to WNT signaling activation.14
Recently, the interaction between b-catenin and PROP1
was described as a new mechanism for the b-catenin-
dependent regulation of pituitary cell lineage determination
in response to WNT signaling. According to this model, the
PROP1/b-catenin protein complex would act as a binary
switch to simultaneously repress the transcription factor
HESX1 and activate the expression of the transcription
factor PIT1.15 Interestingly, both factors are involved in
pituitary cell proliferation and differentiation.
PROP1 is a paired-like homeodomain transcription factor
that is essential for pituitary development and function due
to its regulation of PIT1 expression,16 which is essential for
the terminal differentiation and expansion of somatotropes,
lactotropes and thyrotropes.17 PROP1 is encoded by PROP1,
a homeobox gene with 3 exons. The homeodomain is
characterized by three helices, the third of which is essential
for target gene DNA recognition.18 PROP1 can bind to DNA
via the carboxy-terminus to activate target genes or via the
amino-terminus and the homeodomain to repress target
genes. These results suggest that PROP1 can act as both a
transcriptional activator and repressor.16,19
Patients with loss-of-function mutations in PROP1 pre-
sent with combined pituitary hormonal deficiencies that are
generally associated with pituitary enlargement.20-25
Magnetic resonance imaging of the sellar regions of these
patients can demonstrate a T1 hyperintense signal that
resembles craniopharyngioma-like tumors.
In aGSU-Prop1 transgenic mice, persistent Prop1 expres-
sion may result in increased cellular proliferation, which
would enhance the probability of a tumor-initiating muta-
tion. In fact, these mice exhibit defects consistent with the
dysregulation of pituitary cell proliferation, such as adeno-
matous hyperplasia with the formation of Rathke’s cleft
cysts and tumors. The phenotype of these mice suggests that
dysregulation of PROP1 expression in humans may
contribute to the pathogenesis of pituitary tumors.26
Morbidity and mortality frequently result from the
aggressive nature of craniopharyngiomas as well as their
treatment, which lead to significant medical and social
problems. Therefore, it is critically important to better
elucidate the pathogenesis of this tumor. Thus, the aim of
this study was to analyze PROP1 and CTNNB1 expression
in adamantinomatous craniopharyngiomas and correlate
these findings with the presence of somatic mutations in
CTNNB1.
MATERIALS AND METHODS
Subjects
The study was approved by the ethics committee of the
Hospital das Clı´nicas in Sa˜o Paulo, Brazil, and informed
written consent was obtained from all of the patients’
parents. We analyzed 14 adamantinomatous craniophar-
yngiomas that were obtained during the surgical resections
of children and adolescents (five males and nine females).
The age of these patients ranged from 1.58 to 21.58 years
(mean 10 years). The phenotype of these patients was very
similar. Most patients presented with headaches, visual
deficiencies, hypopituitarism and large tumors, and most
patients required two or more surgical procedures for the
relief of their neurological symptoms. All samples were
used for cDNA sequencing. However, two of the 14 tumor
samples were excluded from the expression analysis due to
their poor RNA quality. b-catenin immunohistochemistry
was performed on ten samples.
RNA extraction and reverse transcription
Total RNA was extracted from fresh-frozen tissues, which
had been preserved in RNAlaterH (Ambion, Austin, TX
USA) at -20 C˚ using the TRIzolH reagent (Invitrogen,
Carlsbad, CA, USA). The elapsed time between tissue
isolation and RNA extraction was approximately one to
two weeks. The integrity of the extracted RNA was
evaluated on a 1% agarose gel, and the concentrations
were determined using a spectrophotometer (Eppendorf
Biophotometer, Hamburg, Germany). The cDNA samples
were obtained from a reverse transcription reaction per-
formed on the same day as RNA extraction and were stored
at -20 C˚. The cDNA was synthesized from 1.25 mg of total
RNA in a final volume of 50 mL, and a final concentration of
25 ng/mL was obtained using the high-capacity cDNA
archive kit (Applied Biosystems, Foster City, CA, USA).
The reverse transcription reaction was performed at 25 C˚ for
10 minutes and was followed by a cycle at 37 C˚ for 120
minutes. Next, the remaining RNA was stored at -80 C˚. The
molecular analyses were most often conducted within two
weeks of cDNA synthesis.
PCR
Exon 3 of CTNNB1 (ENSG00000168036) was amplified
using the primers sense 59-GATTTGATGGAGTTGGACAT-
GG-39 and antisense 59-TGTTCTTGAGTGAAGGACTGAG-
39. The PCR reaction setup was as follows. cDNA (25 ng)
from each tumor sample was added to a 25-mL reaction
mixture containing 5x PCR buffer (50 mM KCL, 1.5 mM
MgCl2 and 10 mM Tris-HCL pH 9.0), 200 mmol of dNTPs,
20 pmol of each primer and 1.5 U of GoTaqH DNA
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Polymerase (Promega, Madison, WI, USA). The PCR reaction
mixture was then denatured for 5 minutes at 94 C˚, cycled 35
times (94 C˚ for 45 sec, 65 C˚ for 45 sec and 72 C˚ for 60 sec)
and incubated at 72 C˚ for 10 minutes for a final extension.
The PCR reaction yielded a fragment of 218 bp. Each of the
amplified fragments was examined using 1.5% agarose gel
electrophoresis, stained by ethidium bromide and visua-
lized under UV light. The PCR products were pretreated
with an enzymatic combination of exonuclease I and shrimp
alkaline phosphatase (United Stated Biochemical Corp.,
Cleveland, OH, USA) and were directly sequenced using
the BigDye terminator cycle sequencing ready reaction kit
(PE Applied Biosystems, Foster City, CA) and an ABI
PRISM 3100 automatic sequencer (Perkin-Elmer Corp.,
Waltham, MA, USA).
Quantitative real-time RT-PCR
The PROP1, PIT1 and CTNNB1 mRNA levels were
measured by quantitative real-time RT-PCR from 12 ada-
mantinomatous craniopharyngiomas using the ABI Prism
7000 sequence detection system (Applied Biosystems, Foster
City, CA, USA). TaqManH gene expression assays were used
to quantify gene expression (PROP1 - Hs00196604_m1; PIT1 -
Hs00230821_m1; CTNNB1 - Hs00355045_m1). The amplifica-
tion reactions were performed in triplicate using 12.5 mL of
TaqManH universal PCR master mix (Applied Biosystems),
2 mL of cDNA (25 ng/mL) and 1.25 mL of TaqManH gene
expression assay solution in a final volume of 25 mL. The
geNorm software was used to identify the most adequate
internal control gene for the normalization of target gene
expression.27 The three most stably expressed housekeep-
ing genes in adamantinomatous craniopharyngiomas were
PGK1 (phosphoglyceratekinase 1 - 4326318E), PPIA (cyclo-
philin A - 4326316E) and HPRT1 (hypoxanthine phosphor-
ibosyltransferase 1 - 4326321E). The geometric mean of the
expression of these three genes was used as the internal
control gene value. A pooled sample of normal pituitary
tissue from 39 adult patients (Human Pituitary Gland Poly
A+ RNA, Clontech, Palo Alto, CA, USA) was used as a
reference for relative quantification using the 2-DDCT
method.28 A no template control (NTC) sample was used
in each amplification plate to exclude the possibility of
contamination. PIT1 expression was also evaluated to
exclude the presence of normal pituitary gene expression
in the craniopharyngioma samples. PIT1 is a transcrip-
tion factor that is a member of the POU domain family,
which is essential for the proliferation and differentiation
of the somatotrope, lactotrope and thyrotrope pituitary
lineages.29 Samples were considered as overexpressed
when they demonstrated a two-fold or greater expression
change over the normal pooled pituitary samples. Un-
detectable expression was defined as a CT value greater
than 34 due to high variability and poor precision of the
relative quantification from the tumor samples above this
CT value.
Immunohistochemistry
Immunohistochemical analyses were performed on 3-mm
paraffin sections that were deparaffinized in xylene and
rehydrated through a series of ethanol treatments. Antigen
retrieval was accomplished by incubating the sections in
10 mM sodium citrate pH 6.0 and heating them with a
steamer. To block endogenous peroxidase activity, sections
were immersed for 30 minutes in a 6% hydrogen peroxide
solution diluted in methanol (v/v) and were then washed
with phosphate buffer (10 mM phosphate buffered saline
(PBS) pH 7.4). Proteins were blocked using CAS-Block
(Zymed). For the detection of b-catenin, monoclonal anti-
body (clone 14, BD) was used at a 15800 dilution, and the
stained cells were incubated at 37 C˚ for 30 minutes and then
at 4 C˚ overnight. The final visualization was carried out by
chromogenic detection using a solution of PBS containing
0.1% diaminobenzidine, 0.06% H2O2 and 1% dimethyl
sulfoxide. The sections were immersed in this solution for 5
minutes at 37 C˚. Counterstaining was performed using
Harris hematoxylin. A known positive control was
included, and sections that were incubated with PBS instead
of the primary antibody served as negative controls.
Statistical analysis
All statistical analyses were performed with SPSS version
16.0 (SPSS, Chicago, IL). Categorical variables were com-
pared using Fisher’s exact test, and p values ,0.05 were
considered significant.
RESULTS
Heterozygous missense mutations in exon 3 of CTNNB1
were found in 9 of the 14 adamantinomatous craniophar-
yngiomas within codons 32, 33, 37 and 41, which affect the
target region of GSK-3b (Table 1). All but two of these
mutations have been previously described in craniophar-
yngiomas.6-9 One of these novel mutations was the result of
an amino acid substitution of aspartic acid, a hydrophilic
amino acid, for valine, a hydrophobic amino acid, at codon
32. The other novel mutation was a serine to proline
replacement at residue 37; both of these amino acids are
classified as polar and uncharged.
CTNNB1 overexpression was found in five of the seven
samples with b-catenin mutations (tumor samples 3, 5, 9, 11,
and 14), and this expression was found to be between 2.5-
and 6.2-fold greater in these samples than in those from the
normal pituitary. Of the five samples without b-catenin
mutations, two were found to have upregulated CTNNB1
expression (fold change of 4.6 and 3.6 for samples 4 and 13,
respectively) (Figure 1). However, this difference did not
reach statistical significance (p = 0.558).
Table 1 - Somatic mutations in exon 3 of CTNNB1 in
patients with adamantinomatous craniopharyngiomas.
Patients
Age
(years) Sex
Coding DNA
sequence change
Amino acid
change
1 9.66 M c.122C.T p.Thr41Ile
2 4 M Not found Not found
3 1.58 F c.110C.T p.Ser37Phe
4 10.58 F Not found Not found
5 9.9 M c.109T.C p.Ser37Pro1
6 21 M Not found Not found
7 2.41 F c.94G.A p.Asp32Phe
8 1.83 M c.122C.T p.Thr41Ile
9 13.58 F c.98C.T p.Ser33Phe
10 17.58 F c.94G.A p.Asp32Phe
11 14.5 F c.98C.G p.Ser33Cys
12 11.66 F Not found Not found
13 9.25 F Not found Not found
14 4 F c.95A.T p.Asp32Val1
1Mutations not previously described in adamantinomatous
craniopharyngiomas.
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The PROP1 mRNA levels were undetectable in 10 of 12
samples. Two of these samples showed both PROP1 and
PIT1 expression, which indicated contamination from
normal pituitary tissue. Therefore, these samples were
discarded from the analysis.
Immunohistochemical staining for b-catenin expression
showed a nuclear staining pattern (Figure 2) in all the
analyzed samples, and this same result was also observed
for those samples without CTNNB1 mutations (Table 2).
DISCUSSION
Craniopharyngiomas are the most common lesions of the
hypothalamo-pituitary region in the child population.1
Despite their benign histological appearance, the aggressive
behavior and the invasiveness of these tumors into pituitary
and parasellar structures, such as the optic nerve and the
hypothalamus, can result in significant neurological seque-
lae and consequently may impair the quality of life.
Mutations in exon 3 of CTNNB, which encodes the GSK-3b
binding domain of b-catenin, have been previously shown to
occur in 16% to 100% of adamantinomatous craniopharyn-
giomas.6-9 In our cohort, CTNNB1 mutations were identified
in 64% of the adamantinomatous craniopharyngiomas. These
mutations were found at codon 32 (n = 3), which flanks the
phosphorylation site of GSK-3b, as well as codons 33 (n = 1),
37 (n = 3) and 41 (n = 2), which affect the serine/threonine
residues of b-catenin that are the target of GSK-3b.14 Recently,
mutations in these codons were shown to be responsible for
increased b-catenin target gene activation, and this increase
was represented by elevated mRNA levels of Axin2 and
BMP4 in craniopharyngioma cells with nuclear b-catenin
accumulation.30 Axin2 is a well-recognized inhibitor and
target gene of b-catenin31, whereas BMP4 plays a crucial role
in tooth development and enhances cell proliferation in
tumors with b-catenin accumulation.32,33
Figure 1 - CTNNB1 gene expression in adamantinomatous craniopharyngiomas with or without somatic CTNNB1 mutations.
Figure 2 - b-catenin immunohistochemical staining showing the
nuclear staining pattern.
Table 2 - Immunohistochemical staining for b-catenin
expression, the mutational analysis and the expression of
CTNNB1 in adamantinomatous craniopharyngiomas.
Patients
Nuclear
staining
CTNNB1
mutation
CTNNB1 expression
(fold number)
1 ++ Yes 0.97
2 Not performed No 1.6
3 +++ Yes 6.2
4 + No 4.5
5 Not performed Yes 4.4
6 Not performed No 1.7
7 + Yes 3.3
8 ++ Yes 2.7
9 + Yes 2.5
10 + Yes 1.9
11 ++ Yes 3.8
12 + No 1.9
13 ++ No 3.5
14 Not performed Yes 3.6
Nuclear staining was classified as follows: +, staining in a maximum of
10% of the cells; ++, staining in 10% to 50% of the cells; +++, staining in
more than 50% of the cells. Expression is represented by the fold change
compared to the normal pituitary pool.
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Interestingly, 71% of the tumors (five out of seven) with
b-catenin somatic mutations were shown to overexpress
CTNNB1, and this result was also observed in 40% of the
tumor samples without b-catenin mutations (two out of
five). Each of the ten samples (seven with CTNNB1
mutations) submitted for immunohistochemical analysis
demonstrated nuclear b-catenin staining (Table 2),
whereas two out of the three non-mutated samples
showed both CTNNB1 overexpression and nuclear b-
catenin staining. These results suggested that CTNNB1
overexpression, which leads to WNT signaling activation,
plays a key role in the tumorigenesis of adamantinomatous
craniopharyngiomas regardless of the presence of
CTNNB1 mutations.
The pathogenesis of adamantinomatous craniopharyngio-
mas that do not have mutations in or display the over-
expression of CTNNB1 remains to be determined. To
investigate other pathways that are likely involved in this
process, we performed a PROP1 expression analysis. This
gene was chosen based on the fact that b-catenin, which is
the only protein shown thus far to be involved in this
pathogenesis, interacts with PROP1 to control pituitary cell
lineage determination15, as well as the fact that transgenic
mice engineered to exhibit persistent expression of Prop1
demonstrate both defects in the control of cellular prolifera-
tion and an increased susceptibility to pituitary tumors.26
Moreover, patients with loss-of-function PROP1 mutations
can present with pituitary enlargement.20-25 Thus, we
investigated whether PROP1 dysregulation could contribute
to the tumorigenesis of adamantinomatous craniopharyn-
giomas. However, PROP1 expression was undetectable in
all the samples, which indicated that expression of the
PROP1 gene most likely does not affect adamantinomatous
craniopharyngioma pathogenesis.
In conclusion, CTNNB1 overexpression was found in the
majority of the adamantinomatous craniopharyngiomas
studied. Our findings also suggest that WNT signaling
activation via b-catenin upregulation plays an important
role in the pathogenesis of adamantinomatous craniophar-
yngiomas regardless of the presence of CTNNB1 mutations.
Additionally, PROP1 dysregulation was not likely involved
in the pathogenesis of adamantinomatous craniopharyngio-
mas in this cohort of patients. However, this study was the
first to analyze PROP1 expression in this type of tumor, and
further studies are necessary to confirm the lack of a role for
PROP1 in this tumorigenesis.
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